Mircescu Gabriel, Capuşă Cristina, Stoian Irina, Vârgolici Bogdana, Barbulescu Carmen, Ursea Nicolae
Dr Carol Davila University Hospital of Nephrology, Bucharest--Romania.
J Nephrol. 2005 Sep-Oct;18(5):599-605.
Since chronic renal failure (CRF) was described as a state of oxidant/antioxidant imbalance augmented after hemodialysis (HD) initiation, we assessed the total antioxidant activity and single antioxidants in sera from uremic patients dialyzed or not, compared to subjects with normal renal function.
Serum total antioxidant activity (TAA--measured as Trolox equivalent antioxidant capacity; mmol/L), total plasma free thiols (Pt-SH; micromol/g protein), albumin (g/dL) and uric acid (mg/dL) were determined in 19 hemodialyzed patients, 15 CRF non-dialyzed patients (serum creatinine (Cr) = 4.4 +/- 2.7 mg/dL) and in 16 healthy controls. The "antioxidant gap" (mmol/L), as a measure of the combined activity of plasma antioxidants other than albumin and uric acid, was calculated.
TAA and the "antioxidant gap" were higher in HD patients (1.21 +/- 0.12 vs. 0.96 +/- 0.13 in the non-HD group, p<0.001, and vs. 0.9 +/- 0.14 in controls, p<0.001, respectively, for TAA; 0.46 +/- 0.15 vs. 0.2 +/- 0.15, p<0.001, and vs. 0.21 +/- 0.16, p<0.001, respectively, for residual antioxidant activity). However, no differences existed in major plasma antioxidant levels (albumin and uric acid) among uremic patients, hemodialyzed or not. Pt-SH were reduced in nondialyzed patients as compared to controls (6.21 +/- 1.1 vs. 7.33 +/- 0.83, p=0.002), but were elevated in HD patients (11.9 +/- 1.1).
These results suggest that HD patients appear to have improved plasma antioxidant status, hyperuricemia not being the sole contributor. Therefore, it seems reasonable to speculate that other antioxidants (thiols or some as yet unrecognized substances) could also be contributors. However, more reliable assays for extracellular antioxidant defense evaluation are required to validate this hypothesis.
由于慢性肾衰竭(CRF)被描述为血液透析(HD)开始后氧化/抗氧化失衡加剧的一种状态,我们评估了透析和未透析的尿毒症患者血清中的总抗氧化活性和单一抗氧化剂,并与肾功能正常的受试者进行了比较。
测定了19例血液透析患者、15例未透析的慢性肾衰竭患者(血清肌酐(Cr)=4.4±2.7mg/dL)和16例健康对照者的血清总抗氧化活性(以Trolox等效抗氧化能力衡量;mmol/L)、血浆总游离巯基(Pt-SH;μmol/g蛋白质)、白蛋白(g/dL)和尿酸(mg/dL)。计算了“抗氧化剂差距”(mmol/L),作为白蛋白和尿酸以外的血浆抗氧化剂联合活性的指标。
血液透析患者的总抗氧化活性和“抗氧化剂差距”较高(总抗氧化活性方面,血液透析组为1.21±0.12,未透析组为0.96±0.13,p<0.001,对照组为0.9±0.14,p<0.001;残余抗氧化活性方面,分别为0.46±0.15、0.2±0.15和0.21±0.16,p<0.001)。然而,尿毒症患者(无论是否进行血液透析)的主要血浆抗氧化剂水平(白蛋白和尿酸)没有差异。未透析患者的Pt-SH水平低于对照组(6.21±1.1 vs. 7.33±0.83,p=0.002),但血液透析患者的Pt-SH水平升高(11.9±1.1)。
这些结果表明,血液透析患者的血浆抗氧化状态似乎有所改善,高尿酸血症并非唯一因素。因此,推测其他抗氧化剂(巯基或一些尚未被认识的物质)也可能起作用似乎是合理的。然而,需要更可靠的细胞外抗氧化防御评估检测方法来验证这一假设。